Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS ) 33.54 +0.26 (+0.78%) Streaming Delayed Price Updated: 2:32 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tema GLP-1, Obesity & Cardiometabolic ETF EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' September 25, 2024 Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line. Via Benzinga EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' July 18, 2024 Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. Via Benzinga EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO July 07, 2024 The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. Via Benzinga Topics ETFs What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients July 05, 2024 A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. Via Investor's Business Daily Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply May 29, 2024 The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to... Via Benzinga Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test April 17, 2024 The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea. Via Investor's Business Daily Healthcare ETFs For The Weight-Loss Drug Boom And Beyond April 08, 2024 Two dominant investing themes over the past year have been AI and weight-loss drugs. Via Talk Markets Topics Artificial Intelligence ETFs Exposures Artificial Intelligence Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. February 23, 2024 Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. Via Investor's Business Daily Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing January 29, 2024 David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga. Via Benzinga Topics ETFs Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market December 04, 2023 Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic Via Benzinga EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads December 01, 2023 Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads. Via Benzinga Topics ETFs Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
